Continuous Lumbar Plexus Block for Postoperative Pain Control After Total Hip Arthroplasty

Postoperative Pain Clinical Trial

Official title:

Continuous Lumbar Plexus Block for Postoperative Pain Control After Total Hip Arthroplasty

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00790179
• Other study ID #: 1989md
• Status: Completed
• Phase: N/A
• First received: November 12, 2008
• Last updated: November 12, 2008
• Start date: January 2003
• Est. completion date: March 2007

Study information

• Verified date: November 2008
• Source: Northwell Health
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Continuous lumbar plexus and femoral blocks have been demonstrated to provide effective postoperative analgesia of the lower extremity following total joint arthroplasty. The purpose of this study was to compare these two techniques when used with intravenous patient-controlled analgesia and the use of patient-controlled analgesia alone for postoperative pain management following unilateral total hip arthroplasty.

Description:

above may be applied

Recruitment information / eligibility

• Status: Completed
• Enrollment: 225
• Est. completion date: March 2007
• Est. primary completion date: January 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• 18-80 years old

• primary diagnosis of osteoarthritis

Exclusion Criteria:

• allergy to local anesthetics

• peripheral neuropathy

• opioid dependency

• dementia

• coagulopathy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pain, Postoperative
• Postoperative Pain

Intervention

Procedure:
• continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA
0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB. Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Northwell Health

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VAS pain scores		at 24 and 48 hours	No
Secondary	hydromorphone consumption,patient satisfaction,distance ambulated, opioid-related side effects		at 24 and 48 hours	No